Psychiatrists have rarely enjoyed a surplus of public trust. During the past 3 years, public trust in psychiatry has been further undermined with accusations that several leading academic psychiatrists failed to disclose financial conflicts of interest. Sen Charles Grassley (R, Iowa), ranking member of the Finance Committee, has thus far accused 7 psychiatrists of failing to disclose income from pharmaceutical companies. As public trust in the pharmaceutical industry has plummeted, the close connection between leading psychiatrists and the pharmaceutical industry, once a sign of progress for the profession, is now cited as evidence of corrupt influence.1
Insel TR. Psychiatrists' Relationships With Pharmaceutical Companies: Part of the Problem or Part of the Solution? JAMA. 2010;303(12):1192–1193. doi:10.1001/jama.2010.317
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: